Invesco NASDAQ Future Gen 200 ETF (QQQS)
| Assets | $7.21M |
| Expense Ratio | 0.20% |
| PE Ratio | n/a |
| Shares Out | 310,000 |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.97% |
| Ex-Dividend Date | Mar 24, 2025 |
| Payout Ratio | n/a |
| 1-Year Return | -9.82% |
| Volume | 1,713 |
| Open | 22.86 |
| Previous Close | 23.24 |
| Day's Range | 22.58 - 22.88 |
| 52-Week Low | 19.55 |
| 52-Week High | 30.71 |
| Beta | 1.48 |
| Holdings | 204 |
| Inception Date | Oct 13, 2022 |
About QQQS
Fund Home PageThe Invesco NASDAQ Future Gen 200 ETF (QQQS) is an exchange-traded fund that is based on the Nasdaq Innovators Completion Cap index. The fund tracks an equal-weighted index of 200 NASDAQ-listed stocks selected based on the value of their patent portfolios. The portfolio excludes the largest 200 stocks listed on NASDAQ. QQQS was launched on Oct 13, 2022 and is issued by Invesco.
Top 10 Holdings
7.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Neonode Inc. | NEON | 0.87% |
| Niagen Bioscience, Inc. | NAGE | 0.81% |
| Akebia Therapeutics, Inc. | AKBA | 0.76% |
| Pro-Dex, Inc. | PDEX | 0.76% |
| AnaptysBio, Inc. | ANAB | 0.72% |
| Microvast Holdings, Inc. | MVST | 0.72% |
| Adaptive Biotechnologies Corporation | ADPT | 0.68% |
| KalVista Pharmaceuticals, Inc. | KALV | 0.68% |
| Ocugen, Inc. | OCGN | 0.67% |
| Fate Therapeutics, Inc. | FATE | 0.67% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2025 | $0.06147 | Mar 28, 2025 |
| Dec 23, 2024 | $0.04816 | Dec 27, 2024 |
| Sep 23, 2024 | $0.11363 | Sep 27, 2024 |
| Mar 18, 2024 | $0.06716 | Mar 22, 2024 |
| Dec 18, 2023 | $0.03706 | Dec 22, 2023 |
| Sep 18, 2023 | $0.02839 | Sep 22, 2023 |
News
Tap Into Small-Cap Healthcare Opportunity With This ETF
In an extension of a long-running theme, biotechnology stocks are disappointing investors again in 2025. Large-cap gauges addressing the industry have performed mostly in line with the S&P 500.
Valuations, Earnings Power Could Lift Small-Caps This Year
There's roughly 10 months left in 2025. That's ample time for small-caps stocks and related ETFs to potentially deliver on long-awaited outperformance of large-caps counterparts.
How To Avoid The Worst Style ETFs For Q1 2025
ETF issuance is profitable for Wall Street, leading to an overwhelming number of ETFs that may not serve investors' best interests. Avoid ETFs with less than $100 million in assets due to inadequate l...
Invesco takes the regulatory steps to expand its ETF business in Japan
ATLANTA , June 20, 2023 /PRNewswire/ -- Invesco Capital Management LLC, an investment adviser managing an extensive family of exchange-traded funds (ETFs), announced today that our global ETF business...